CA2747376A1 - Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response - Google Patents

Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response Download PDF

Info

Publication number
CA2747376A1
CA2747376A1 CA2747376A CA2747376A CA2747376A1 CA 2747376 A1 CA2747376 A1 CA 2747376A1 CA 2747376 A CA2747376 A CA 2747376A CA 2747376 A CA2747376 A CA 2747376A CA 2747376 A1 CA2747376 A1 CA 2747376A1
Authority
CA
Canada
Prior art keywords
carbon atoms
inclusive
branched
straight chain
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2747376A
Other languages
English (en)
French (fr)
Inventor
Charles N. Serhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of CA2747376A1 publication Critical patent/CA2747376A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
CA2747376A 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response Abandoned CA2747376A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12520599P 1999-03-18 1999-03-18
US60/125,205 1999-03-18
CA2615917A CA2615917C (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2615917A Division CA2615917C (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response

Publications (1)

Publication Number Publication Date
CA2747376A1 true CA2747376A1 (en) 2000-09-21

Family

ID=22418647

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2615917A Expired - Fee Related CA2615917C (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
CA002367909A Expired - Fee Related CA2367909C (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
CA2747376A Abandoned CA2747376A1 (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2615917A Expired - Fee Related CA2615917C (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
CA002367909A Expired - Fee Related CA2367909C (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response

Country Status (11)

Country Link
US (6) US6387953B1 (enExample)
EP (1) EP1165066B1 (enExample)
JP (1) JP4440481B2 (enExample)
AT (1) ATE310512T1 (enExample)
AU (1) AU775140B2 (enExample)
CA (3) CA2615917C (enExample)
DE (1) DE60024242T2 (enExample)
DK (1) DK1165066T3 (enExample)
ES (1) ES2249257T3 (enExample)
HK (1) HK1043307B (enExample)
WO (1) WO2000054767A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
PT1163204E (pt) * 1999-03-18 2005-11-30 Brigham & Womens Hospital Compostos a base de lipoxina e sua utilizacao
DE60044335D1 (de) 1999-03-18 2010-06-17 Brigham & Womens Hospital 16-phenoxy-lipoxin analoge zur medizinischen verwendung
AU775140B2 (en) * 1999-03-18 2004-07-22 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
GB2362140B (en) * 2000-05-12 2003-03-05 Autoliv Dev Improvements in or relating to an apparatus for a method of folding an air-bag
JP2005508282A (ja) * 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル 新規な脈管形成抑制剤としてのリポキシン類似物
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
EP1441715B1 (en) * 2001-11-06 2013-02-27 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
EP1911448B1 (en) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP2361622A1 (en) 2001-12-18 2011-08-31 The Brigham and Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
ATE449057T1 (de) * 2002-08-12 2009-12-15 Brigham & Womens Hospital Resolvine: biotemplate zur durchführung therapeutischer anwendungen
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US7615212B2 (en) * 2004-02-26 2009-11-10 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
JP2009515991A (ja) * 2005-11-18 2009-04-16 トラスティーズ オブ ボストン ユニバーシティ レゾルビンを使用する骨喪失の処置および防止
PE20081200A1 (es) 2006-12-04 2008-11-06 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4
US20120220658A1 (en) * 2009-10-21 2012-08-30 University Of Medicine And Dentistry Of New Jersey Method for Treating Sepsis or Septic Shock
CA3052271A1 (en) 2017-01-31 2018-08-09 The Brigham And Women's Hospital, Inc. Alx receptor ligands define a biochemical endotype for inflammation-based diseases
JP7550143B2 (ja) 2018-10-09 2024-09-12 ユニバーシティ オブ ロチェスター 外陰膣障害の治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
EP1657233A1 (en) * 1993-06-15 2006-05-17 The Brigham & Women's Hospital, Inc. Lipoxin compounds
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
DE60044335D1 (de) * 1999-03-18 2010-06-17 Brigham & Womens Hospital 16-phenoxy-lipoxin analoge zur medizinischen verwendung
PT1163204E (pt) * 1999-03-18 2005-11-30 Brigham & Womens Hospital Compostos a base de lipoxina e sua utilizacao
AU775140B2 (en) * 1999-03-18 2004-07-22 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response

Also Published As

Publication number Publication date
US6387953B1 (en) 2002-05-14
US20020143069A1 (en) 2002-10-03
ES2249257T3 (es) 2006-04-01
US20080081838A1 (en) 2008-04-03
US20020132847A1 (en) 2002-09-19
EP1165066B1 (en) 2005-11-23
WO2000054767A1 (en) 2000-09-21
ATE310512T1 (de) 2005-12-15
US7132451B2 (en) 2006-11-07
AU3880600A (en) 2000-10-04
US6710084B2 (en) 2004-03-23
CA2367909A1 (en) 2000-09-21
JP4440481B2 (ja) 2010-03-24
CA2615917A1 (en) 2000-09-21
CA2615917C (en) 2011-10-04
US20040192785A1 (en) 2004-09-30
US20080312323A1 (en) 2008-12-18
DK1165066T3 (da) 2006-03-06
CA2367909C (en) 2008-02-12
JP2002539159A (ja) 2002-11-19
DE60024242T2 (de) 2006-12-14
DE60024242D1 (de) 2005-12-29
HK1043307B (en) 2006-02-03
EP1165066A1 (en) 2002-01-02
AU775140B2 (en) 2004-07-22
HK1043307A1 (en) 2002-09-13
US6703423B2 (en) 2004-03-09

Similar Documents

Publication Publication Date Title
CA2747376A1 (en) Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
CA2645558A1 (en) Regulation of phospholipase d activity
CA2465117A1 (en) Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
CA2134679C (en) Soluble analogs of probucol
EP1108427A3 (en) Compositions for and uses thereof for altering gene expression with phenylacetate and derivatives thereof
CA2348993A1 (en) Substituted phenethylsulfones and method of reducing tnf.alpha. levels
JP2002539159A5 (enExample)
RU98122210A (ru) Производные андростена
RU95115542A (ru) Липосомальная фармацевтическая композиция для внутреннего введения
RU96117041A (ru) Применение производных 2-гидрокси-5-фенилазобензойной кислоты в качестве химиопрофилактических и химиотерапевтических агентов при раке ободочной кишки
KR890005124A (ko) 세펨 화합물 및 이의 제조방법
JP2005533897A5 (enExample)
CA2467580A1 (en) Use of lipoxin analogs to promote cell defense against gram-negative infections
CA2338854A1 (en) Nitric esters and nitrate salts of specific drugs
JP2002520286A5 (enExample)
ES8205762A1 (es) Procedimiento para la preparacion de oximas de acidos piru- vicos
JP2001354558A5 (enExample)
CA2294274A1 (en) Compositions and methods for reversibly increasing permeability of biomembranes
KR910700230A (ko) 신규 히드록실아민 유도체
KR920000715A (ko) 신규의 n- 벤질-n1- 페닐-및- 펜알킬- 티오우레아류
KR950002753A (ko) 연골 보호제
CA2482327A1 (en) Pendant fatty acid imaging agents
CA2030911A1 (en) Pharmaceutical preparations
JPS5527107A (en) N-(2-ethylhexyl)-crotonylamide and carcinostatic substance containing the same
RU96121791A (ru) Применение производных ксантина для снижения патологической гиперактивности эозинофильных гранулоцитов, новые производные ксантина и способ их получения

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141223